Launched early last year, Clerkenwell Health still has a relatively small team (with just 15 employees) but has big ambitions. The company tells us it is currently working with three clients, including drug development company Octarine Bio, to design and deliver clinical trials for psilocybin and its analogues, but that it is looking to expand into other substances in the near future. Clerkenwell Health is also developing a patient-facing ehealth app and launching a therapist training programme, all in the hopes of making psychedelic treatments viable at scale. Eventually, it aims to be the go-to partner for all stages of psychedelic therapy and drug development.